Effects of the Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Individuals

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2010 Apr 24

PMID 20414637

Citations 16

Authors

A Zanchi

M Maillard

F R Jornayvaz

M Vinciguerra

P Deleaval

J Nussberger

M Burnier

A Pechere-Bertschi

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Glitazones are powerful insulin sensitisers prescribed for the treatment of type 2 diabetes. Their use is, however, associated with fluid retention and an increased risk of congestive heart failure. We previously demonstrated that pioglitazone increases proximal sodium reabsorption in healthy volunteers. This study examines the effects of pioglitazone on renal sodium handling in individuals prone to insulin resistance, i.e. those with diabetes and/or hypertension.

Methods: In this double-blind randomised placebo-controlled four-way crossover study, we examined the effects of pioglitazone (45 mg daily during 6 weeks) or placebo on renal, systemic and hormonal responses to changes in sodium intake in 16 individuals, eight with type 2 diabetes and eight with hypertension.

Results: Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake. A compensatory increase in brain natriuretic peptide levels was observed. In spite of sodium retention, pioglitazone dissociated the blood-pressure response to salt and abolished salt sensitivity in salt-sensitive individuals.

Conclusions/interpretation: Pioglitazone increases diurnal proximal sodium retention in diabetic and hypertensive individuals. These effects cause fluid retention and may contribute to the increased incidence of congestive heart failure with glitazones.

Trial Registration: ClinicalTrial.gov NCT01090752

Funding: Hypertension Research Foundation Lausanne.

Citing Articles

Interaction between Nuclear Receptor and Alpha-Adrenergic Agonist Subtypes in Metabolism and Systemic Hemodynamics of Spontaneously Hypertensive Rats.

Afzal S, Sattar M, Albokhadaim I, Attiq A, Kandeel M, Abdul Manap A PPAR Res. 2024; 2024:5868010.

PMID: 38899161 PMC: 11186691. DOI: 10.1155/2024/5868010.

Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.

Josloff K, Beiriger J, Khan A, Gawel R, Kirby R, Kendrick A J Cardiovasc Dev Dis. 2022; 9(12).

PMID: 36547416 PMC: 9786069. DOI: 10.3390/jcdd9120419.

Salt-Sensitivity of Blood Pressure and Insulin Resistance.

Ertuglu L, Elijovich F, Laffer C, Kirabo A Front Physiol. 2021; 12:793924.

PMID: 34966295 PMC: 8711096. DOI: 10.3389/fphys.2021.793924.

Failure to vasodilate in response to salt loading blunts renal blood flow and causes salt-sensitive hypertension.

Wu J, Agbor L, Fang S, Mukohda M, Nair A, Nakagawa P Cardiovasc Res. 2020; 117(1):308-319.

PMID: 32428209 PMC: 7797211. DOI: 10.1093/cvr/cvaa147.

Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials.

Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell N BMJ. 2020; 368:m315.

PMID: 32094151 PMC: 7190039. DOI: 10.1136/bmj.m315.

References

Zanchi A, Perregaux C, Maillard M, Cefai D, Nussberger J, Burnier M . The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. Am J Physiol Endocrinol Metab. 2006; 291(6):E1228-34. DOI: 10.1152/ajpendo.00171.2006. View

Mather K, Hunt A, Steinberg H, Paradisi G, Hook G, Katz A . Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001; 86(11):5457-64. DOI: 10.1210/jcem.86.11.7880. View

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View

Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B . Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993; 22(3):339-47. DOI: 10.1161/01.hyp.22.3.339. View

GOSSE , Ansoborlo , Jullien V , Lemetayer , Clementy . Ambulatory blood pressure and left ventricular hypertrophy. Blood Press Monit. 1997; 2(2):70-74. View

Basu A, Jensen M, McCann F, Mukhopadhyay D, Joyner M, Rizza R . Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006; 29(3):510-4. DOI: 10.2337/diacare.29.03.06.dc05-2004. View

Tiwari S, Blasi E, Heyen J, McHarg A, Ecelbarger C . Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res. 2008; 57(5):383-92. DOI: 10.1016/j.phrs.2008.03.013. View

Zhang H, Zhang A, Kohan D, Nelson R, Gonzalez F, Yang T . Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A. 2005; 102(26):9406-11. PMC: 1166599. DOI: 10.1073/pnas.0501744102. View

Hwang Y, Lee E, Lee W, Cha B, Yoon K, Park K . Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients. Metabolism. 2008; 57(4):479-87. DOI: 10.1016/j.metabol.2007.11.008. View

10.

Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K . Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002; 87(6):2784-91. DOI: 10.1210/jcem.87.6.8567. View

11.

Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G . Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol. 2006; 17(12):3482-90. DOI: 10.1681/ASN.2006060606. View

12.

Magnin J, Decosterd L, Centeno C, Burnier M, Diezi J, Biollaz J . Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: variability of urine matrices circumvented by cation exchange solid phase extraction. Pharm Acta Helv. 1996; 71(4):237-46. DOI: 10.1016/s0031-6865(96)00020-9. View

13.

Yang T, Soodvilai S . Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008; 2008:943614. PMC: 2531205. DOI: 10.1155/2008/943614. View

14.

Nussberger J, Waeber B, Brunner H, Burris J, Vetter W . Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. J Lab Clin Med. 1984; 104(5):789-96. View

15.

Nussberger J, Fasanella dAmore T, Porchet M, Waeber B, Brunner D, Brunner H . Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987; 9(1):39-44. View

16.

Sarafidis P, Nilsson P . The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press. 2006; 15(3):135-50. DOI: 10.1080/08037050600853720. View

17.

Smith S, de Jonge L, Volaufova J, Li Y, Xie H, Bray G . Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2004; 54(1):24-32. DOI: 10.1016/j.metabol.2004.07.008. View

18.

Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J . Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol. 2009; 20(4):721-9. PMC: 2663822. DOI: 10.1681/ASN.2008040415. View

19.

Kim S, Hur K, Kim H, Shim W, Ahn C, Park S . The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. Eur J Endocrinol. 2007; 157(2):167-74. DOI: 10.1530/EJE-07-0043. View

20.

Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner H, Burnier M . Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004; 89(3):1140-5. DOI: 10.1210/jc.2003-031526. View